

Survival at all costs

Editorial Catherine Armitage, Bec Crew, Rebecca Dargie, Gemma Conroy, David Payne **Analysis** Bo Wu, Catherine Cheung **Art & design** Madeline Hutchinson, Tanner Maxwell, Wojtek Urbanek **Production** Jason Rayment, Ian Pope, Nick Bruni, Bob Edenbach, Joern Ishikawa **Marketing & PR** Claire Hodge **Sales & partner content** Sabrina Ma, Jennie Xu, Nicole Yu, Pinky Zhang, Alex Yu, Yingying Zhou, Ruffi Lu, Chris Gilloch, Drew Dargis, JALissa Hamilton, Yuki Fujiwara, Soon Kim, Eri Shimoyama, Ikuko Oba, Shoko Hasegawa, Yoshiko Sugita, Chika Takeda, Natsumi Penberthy **Publishing** Rebecca Jones, Richard Hughes, David Swinbanks.

Nature Index Cancer 2020

Nature Index Cancer 2020, a supplement to *Nature*, is produced by Nature Research, the flagship science portfolio of Springer Nature. This publication is based on data from Nature Index, a Nature Research database with a website maintained and made freely available at natureindex.com.

Nature Editorial Offices

The Campus, 4 Crinan Street,
London N1 9XW, UK
Tel: +44 (0)20 7833 4000
Fax: +44 (0)20 7843 4596/7

Customer services

To advertise with the Nature Index, please visit natureindex.com or email clientservicesfeedback@nature.com
Copyright © 2020 Springer Nature Limited, part of Springer Nature.

All rights reserved.

Some analysts are cynical about the apparent mismatch between spending and outcomes in what's disparagingly called 'the cancer industry'. How can cancer be the second leading cause of death globally, responsible for an estimated 9.6 million deaths in 2018, when a single institution (the US National Institutes of Health, NIH) spent US\$24.4 billion on cancer research in the past four years, not to mention outlays by so many other funders?

As the graph on page S7 shows, researchers are nudging the dial on some types of cancer more than others. This Nature Index supplement focuses on three – cervical, prostate and melanoma – as a lens through which to view the kinds of preventions and treatments that are lengthening survival rates, at least in high-income countries.

Dimensions data provide interesting comparisons on value for money. As a rough indication, looking at the top ten funders' total grants for cancer research from 2010 to 2019 beside their cancer research publications over the same period, the average for the National Natural Science Foundation of China is US\$21,902 per publication. By contrast, for the US National Cancer Institute, part of the NIH and the world's biggest funder of cancer research, it is US\$129,624 per article.

The above analysis is blind to article quality. For that, the indicator is publication in the 82 high-quality journals selected by experts for inclusion in the Nature Index, which, it should be noted, does not include clinical sciences journals. In cancer, as in every other field, China's rise is striking. Its cancer research in the Nature Index rose by an estimated 114.9% from 2015 to 2019, according to our key metric, Share, a fractional count of the proportion of the country's affiliated authors on each article. The number of cancer research articles published in Nature Index journals, identified through a search using Dimensions, grew by 25.8% over the same period, more than four times the growth for articles overall. One reason that cancer outcomes seem not to be improving in line with research output is that improved treatments have not been accessible to all, as our stories about cervical and prostate cancer explain (pages S2 and S5). Therapies, let alone the latest treatments, may be out of reach in the low- and middle-income countries where 70% of global cancer deaths occur. That's not a problem science alone can solve.

Catherine Armitage
Chief editor

**On the cover**

Artistic rendition of a breast cancer cell disintegrating, from an image by Anne Weston, Francis Crick Institute.

Contents

- S2 A global drive towards elimination**
The push to eradicate cervical cancer.
- S5 A closer look at a revered robot**
Widespread preference for robotic surgery comes at a cost.
- S14 Cellular roadblocks trip melanoma hijackers**
A game-changing class of immunotherapy drugs.
- S24 Coming at cancer from all angles**
The researchers making a difference.
- S30 The tables**
How the world's institutions stack up in cancer research.